Log In
Print this Print this

pirotinib (KBP-5209, KBP5209)

  Manage Alerts
Collapse Summary General Information
Company Sihuan Pharmaceutical Holdings Group Ltd.
DescriptionSecond-generation, irreversible pan-EGFR tyrosine kinase inhibitor
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionEpidermal growth factor (EGF) receptor kinase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today